Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B - Cooksley, W G E; Piratvisuth, T; Lee, S-D; Mahachai, V; Chao, Y-C; Tanwandee, T; Chutaputti, A; Chang, W Yu; Zahm, F E; Pluck, N (Journal of viral hepatitis, 2003)
Keywords: Adolescent; Adult; Aged; Confidence Intervals; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Hepatitis B e Antigens - immunology; Hepatitis B, Chronic - drug therapy; Hepatitis B, Chronic - immunology; Humans; Injections, Subcutaneous; Interferon-alpha - administration & dosage; Interferon-alpha - adverse effects; Male; Middle Aged; Polyethylene Glycols - administration & dosage; Polyethylene Glycols - adverse effects; Recombinant Proteins; Reference Values; Risk Assessment; Serologic Tests; Treatment Outcome